Abstract
Hormonal therapy plays an integral role in the management of the majority of women with breast cancer who can be considered to have hormone-dependent breast cancer because of the presence of the molecular predictive markers, estrogen receptor and progesterone receptor. Numerous hormonal agents are available from multiple classes of drugs, including selective estrogen receptor modulators, aromatase inhibitors, progestins, androgens, and luteinizing hormone-releasing hormone analogues. Multiple clinical trials involving these agents have been conducted which permit an evidence-based approach to the development of a sequencing strategy for treatment of women with breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 332-337 |
Number of pages | 6 |
Journal | Breast Journal |
Volume | 8 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2002 |
Keywords
- Adjuvant
- Breast cancer
- Hormonal therapy
- Metastatic
- Sequencing
ASJC Scopus subject areas
- Internal Medicine
- Surgery
- Oncology